Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
24.11
+0.25 (1.05%)
Apr 14, 2026, 4:00 PM EDT - Market closed
Elanco Animal Health Revenue
In the year 2025, Elanco Animal Health had annual revenue of $4.72B with 6.22% growth. Elanco Animal Health had revenue of $1.14B in the quarter ending December 31, 2025, with 12.16% growth.
Revenue (ttm)
$4.72B
Revenue Growth
+6.22%
P/S Ratio
2.55
Revenue / Employee
$476,263
Employees
9,900
Market Cap
12.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.72B | 276.00M | 6.22% |
| Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
| Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
| Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
| Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
| Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
| Dec 31, 2019 | 3.07B | 4.20M | 0.14% |
| Dec 31, 2018 | 3.07B | 177.80M | 6.15% |
| Dec 31, 2017 | 2.89B | -24.50M | -0.84% |
| Dec 31, 2016 | 2.91B | 4.40M | 0.15% |
| Dec 31, 2015 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Viatris | 14.30B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
ELAN News
- 5 days ago - Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* - PRNewsWire
- 7 weeks ago - Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results - PRNewsWire
- 7 weeks ago - Elanco to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Elanco Announces Updates to Board of Directors - PRNewsWire
- 2 months ago - Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement - PRNewsWire
- 3 months ago - Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PRNewsWire
- 4 months ago - Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs - PRNewsWire